Morepen LaboratoriesNSE:MOREPENLAB +0.67%78 Return-on-Tangible-Asset is 3.47% as of Mar. 2026, which is 43% below its 10-year median of 6.14. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 78/100 and a GF Value™ of ₹49.90 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Morepen Laboratories ranks better than 61.59% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Morepen Laboratories's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹630 Mil. Morepen Laboratories's average total tangible assets for the quarter that ended in Mar. 2026 was ₹18,172 Mil. Therefore, Morepen Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 3.47%.
The historical rank and industry rank for Morepen Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
NSE:MOREPENLAB'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.92 Med: 6.14 Max: 14.45
Current: 5.61
During the past 13 years, Morepen Laboratories's highest Return-on-Tangible-Asset was 14.45%. The lowest was 3.92%. And the median was 6.14%.
NSE:MOREPENLAB's Return-on-Tangible-Asset is ranked better than 61.59% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs NSE:MOREPENLAB: 5.61
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Morepen Laboratories Return-on-Tangible-Asset Related Terms
Morepen Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MOREPENLAB vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 3.47% mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Return-on-Tangible-Asset of 3.47% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Morepen Laboratories and its competitors. This is 43% below median its historical median of 6.14. Over the past decade, Morepen Laboratories' Return-on-Tangible-Asset has ranged from 3.92 to 14.45. According to the industry distribution chart, Morepen Laboratories ranks #386 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 38.4%.
Is Morepen Laboratories' Return-on-Tangible-Asset too high?
Morepen Laboratories' current Return-on-Tangible-Asset of 3.47% is 43% below median its 10-year median of 6.14. Over the past 10 years, this metric has ranged from a low of 3.92 to a high of 14.45. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Morepen Laboratories' value of 3.47% is 9.8% above this industry median. Based on the distribution chart, Morepen Laboratories ranks #386 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #386 out of 1005 companies for Return-on-Tangible-Asset. This puts Morepen Laboratories in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.16. Morepen Laboratories' value of 3.47% is 9.8% above this benchmark. Historically, Morepen Laboratories' own Return-on-Tangible-Asset has ranged from 3.92 to 14.45 over the past decade. While the company's 10-year median is 6.14 vs. the industry median of 3.16, Morepen Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current Return-on-Tangible-Asset of 3.47% is 9.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current Return-on-Tangible-Asset is 3.47%, which is 43% below median its own 10-year median of 6.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹49.90, compared to a current price of ₹61.19 — trading 22.6% above its estimated fair value. The current Return-on-Tangible-Asset is 3.47%, which is 43% below median its 10-year median of 6.14 and 9.8% above the Drug Manufacturers industry median of 3.16. Morepen Laboratories' overall GF Score™ is 78/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Return-on-Tangible-Asset is 3.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹61.19 is trading 22.6% above its estimated GF Value™ of ₹49.90.
GuruFocus considers Morepen Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
Return-on-Tangible-Asset: 3.47% (43% below median its 10-year median of 6.14)
GF Value™: ₹49.90 vs. price of ₹61.19 (22.6% above fair value)
Industry Position: 9.8% above the Drug Manufacturers median (#386 of 1005)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
78GF Score
Get the complete analysis for NSE:MOREPENLAB
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
